ÌÅÄËÀÉÍ.ÐÓ
Ñîäåðæàíèå æóðíàëà

Àðõèâ

Ðåäàêöèÿ
Ó÷ðåäèòåëè

Ôåäåðàëüíîå ãîñóäàðñòâåííîå áþäæåòíîå ó÷ðåæäåíèå íàóêè
Èíñòèòóò òåîðåòè÷åñêîé è ýêñïåðèìåíòàëüíîé áèîôèçèêè
Ðîññèéñêîé àêàäåìèè íàóê


ÎÎÎ "ÈÖ ÊÎÌÊÎÍ"

Àäðåñ ðåäàêöèè è ðåêâèçèòû

192012, Ñàíêò-Ïåòåðáóðã, óë.Áàáóøêèíà, ä.82 ê.2, ëèòåðà À, êâ.378

ISSN 1999-6314


Êëèíè÷åñêàÿ ìåäèöèíà » Òåðàïèÿ • Èíôåêöèîííûå áîëåçíè

Òîì: 11
Ñòàòüÿ: « 47 »
Ñòðàíèöû:. 554-574
Îïóáëèêîâàíà â æóðíàëå: äåêàáðü 2010 ã.

English version


¹ ãîñ. ðåãèñòðàöèè: 0421000002047

Èììóíîãåíåòè÷åñêèå ôàêòîðû ïàòîãåíåçà HCV−èíôåêöèè

Ðîìàíîâ À.Î., Áåëÿåâà Ò.Â., Ýñàóëåíêî Å.Â.

Ñàíêò-Ïåòåðáóðãñêèé ãîñóäàðñòâåííûé ìåäèöèíñêèé óíèâåðñèòåò
èì. àêàä. È.Ï. Ïàâëîâà


Ðåçþìå
Âèðóñ ãåïàòèòà Ñ îáëàäàåò âûñîêîé ñïîñîáíîñòüþ ê ïåðñèñòåíöèè è âûçûâàåò õðîíè÷åñêèé ãåïàòèò ñ ïîâûøåííûì ðèñêîì ðàçâèòèÿ öèððîçà. Èììóííûé îòâåò îðãàíèçìà èìååò óíèêàëüíóþ ðîëü, òàê êàê íå òîëüêî ýëèìèíèðóåò âèðóñ, íî è âûçûâàåò ïîâðåæäåíèå ïå÷åíè.  ñòàòüå ðàññìàòðèâàþòñÿ èììóíîãåíåòè÷åñêèå ôàêòîðû, íå îòíîñÿùèåñÿ ê ñèñòåìå HLA, ñ öåëüþ ïîêàçàòü êàê èììóííàÿ ñèñòåìà õîçÿèíà âçàèìîäåéñòâóåò ñ âèðóñíûìè êîìïîíåíòàìè.


Êëþ÷åâûå ñëîâà
ãåïàòèò Ñ; öèððîç; èììóíîãåíåòèêà, CTLA-4, MBL.



(ñòàòüÿ â ôîðìàòå PDF. Äëÿ ïðîñìîòðà íåîáõîäèì Adobe Acrobat Reader)



îòêðûòü ñòàòüþ â íîâîì îêíå

Ñïèñîê ëèòåðàòóðû

1. Abrams J.R., Kelley S.L., Hayes E. et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells // J. Exp. Med. – 2000. – Vol. 192, ¹5. – Ð. 681 – 694.


2. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome // Semin Liver Dis. – 2000. – Vol. 20, ¹1. – P. 17 – 35.


3. Alves Pedroso M.L., Boldt A.B., Pereira-Ferrari L, et al. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy // Clin. Exp. Immunol. – 2008. – Vol. 152, ¹2. – Ð. 258 – 264.


4. Bisbal C., Silverman R.H. Diverse functions of RNase L and implications in


pathology // Biochimie. – 2007. – Vol. 89, ¹ 6-7. – Ð. 789 – 798.


5. Bour-Jordan H., Bluestone J.A. Regulating the regulators: costimulatory signals


control the homeostasis and function of regulatory T cells // Immunol. Rev. – 2009. Vol. 229,


¹1. – Ð. 41 – 66.


6. Brown E.E., Zhang M., Zarin-Pass R., et al. MBL2 and hepatitis C virus infection


among injection drug users // BMC Infect. Dis. – 2008. – Vol. 1, ¹8. – Ð. 57.


7. Brown K.S., Ryder S.D., Irving W.L., et al. Mannan binding lectin and viral


hepatitis // Immunol. Lett. – 2007. – Vol. 108, ¹1. – P. 34 – 44.


8. Carreno B.M., Bennett F., Chau T.A. et al. CTLA-4 (CD152) can inhibit T cell


activation by two different mechanisms depending on its level of cell surfaceexpression // J.


Immunol. – 2000. – Vol. 165, ¹3. – P. 1352 – 1356.


9. Casey G., Neville P.J., Plummer S.J. et al. RNASEL Arg462Gln variant is


implicated in up to 13% of prostate cancer cases // Nat. Genet. – 2002. – Vol. 32, ¹4. – Ð. 581 – 583.


10. Cedzynski M., Szemraj J., Swierzko A.S. et al. Mannan-binding lectin insufficiency


in children with recurrent infections of the respiratory system // Clin. Exp. Immunol. – 2004. –


Vol. 136, ¹2. – Ð. 304 – 311.


11. Chambers C.A., Sullivan T.J., Allison J.P. Lymphoproliferation in CTLA-4-


deficient mice is mediated by costimulation-dependent activation of CD4+ T cells // Immunity. –


1997. – Vol. 7, ¹6. – Ð. 885 – 895.


12. Chaplin D.D. Overview of the immune response // J. Allergy Clin. Immunol. – 2010. – Vol. 125, ¹2, Suppl. 2. – Ð. 3 – 23.


13. Cho M.L., Kim J.Y., Ko H.J. et al. The MCP-1 promoter -2518 polymorphism in


Behcet's disease: correlation between allele types, MCP-1 production and clinical symptoms


among Korean patients // Autoimmunity. – 2004. – Vol. 37, ¹1. – Ð. 77 – 80.


14. Collins M., Ling V., Carreno B.M. The B7 family of immune-regulatory ligands //


Genome. Biol. – 2005 – Vol. 6, ¹6. – Ð. 223.


15. Crawford A., Wherry E.J. The diversity of costimulatory and inhibitory receptor


pathways and the regulation of antiviral T cell responses // Curr. Opin. Immunol. – 2009. –


Vol. 21, ¹2. – Ð. 179 – 186.


16. Dariavach P., Mattei M.G., Golstein P., Lefranc MP. Human Ig superfamily CTLA-


4 gene: chromosomal localization and identity of protein sequence between murine and human


CTLA-4 cytoplasmic domains // Eur. J. Immunol. – 1988. – Vol. 18, ¹12. – Ð. 1901 – 1905.


17. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant


protein-1 (MCP-1): an overview // J. Interferon Cytokine Res. – 2009. – Vol. 29, ¹6. – Ð. 313 – 326.


18. Dobaczewski M., Frangogiannis N.G. Chemokines and cardiac fibrosis // Front.


Biosci. – 2009. – Vol. 1, ¹1. – Ð. 391 – 405.


19. Donner H., Seidl C., Braun J. et al. CTLA4 gene haplotypes cannot protect from


IDDM in the presence of high-risk HLA DQ8 or DQ2 alleles in German families // Diabetes. –


1998. – Vol. 47, ¹7. – Ð. 1158 – 1160.


20. Dore G.J., Freeman A.J., Law M., Kaldor J.M. Is severe liver disease a common


outcome for people with chronic hepatitis C? // J. Gastroenterol. Hepatol. – 2002. – Vol. 17, ¹4. – Ð. 423 – 430.


21. Dumestre-Perard C., Ponard D., Arlaud G.J. et al. Evaluation and clinical interest of


mannan binding lectin function in human plasma // Mol. Immunol. – 2002. – Vol. 39, ¹ 7-8. – Ð. 465 – 473.


22. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive


immune responses // Cel.l Res. – 2010. - – Vol. 20, ¹ 1. – Ð. 34 – 50.


23. Dunning A.M., Ellis P.D., McBride S. A transforming growth factorbeta1 signal


peptide variant increases secretion in vitro and is associated with increased incidence of invasive


breast cancer // Cancer Res. – 2003. – Vol. 63, ¹ 10 – Ð. 2610 – 2615


24. Finzer P., Soto U., Delius H. et al. Differential transcriptional regulation of the


monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells: the role of the chromatin structure and AP-1 composition // Oncogene – 2000. – Vol. 19, ¹ 29. – Ð. 3235 – 3244.


25. Friedman S.L. Liver fibrosis - from bench to bedside // J. Hepatol. – 2003. – Vol. 38, Suppl 1. – P. 38 – 53.


26. Garred P., Madsen H.O. Genetic Susceptibility to Sepsis: A Possible Role for


Mannose-binding Lectin // Curr. Infect Dis. Rep. – 2004 – Vol. 6, ¹ 5. – Ð. 367 – 373.


27. Garred P., Pressler T., Lanng S. et al. Mannose-binding lectin (MBL) therapy in an


MBL-deficient patient with severe cystic fibrosis lung disease // Pediatr. Pulmonol. – 2002. –


Vol. 33, ¹ 3. – Ð. 201 -207.


28. Gewaltig J., Mangasser-Stephan K., Gartung C. et al. Association of


polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of


HCV-induced liver fibrosis // Clin. Chim. Acta. – 2002. – Vol. 316, ¹ 1-2. – Ð. 83 – 94.


29. Glas J., Torok H.P., Tonenchi L. et al. The -2518 promotor polymorphism in the


MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection //


Gastroenterology. – 2004. – Vol. 126, ¹ 7. – Ð. 1930 – 1931.


30. Gleizes P.E., Munger J.S., Nunes I. et al. TGF-beta latency: biological significance


and mechanisms of activation // Stem. Cells. – 1997. – Vol. 15, ¹ 3. – Ð. 190 – 197.


31. Hardie W.D., Le Cras T.D., Jiang K. et al. Conditional expression of transforming


growth factor-alpha in adult mouse lung causes pulmonary fibrosis // Am. J. Physiol. Lung Cell.


Mol. Physiol. – 2004. – Vol. 286, ¹ 4. – Ð. 741 – 749.


32. Hart M.L., Saifuddin M., Spear G.T. Glycosylation inhibitors and neuraminidase


enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding


lectin // J. Gen. Virol. – 2003. – Vol. 84, ¹ 2. – Ð. 353 – 360.


33. Kilpatrick D.C., Delahooke T.E., Koch C., Turner M.L., Hayes P.C. Mannanbinding


lectin and hepatitis C infection // Clin. Exp. Immunol. – 2003. – Vol. 132, ¹ 1 – Ð. 92 – 95.


34. Hodi F.S. Cytotoxic T-lymphocyte-associated antigen-4 // Clin. Cancer Res. –


2007. – Vol. 13, ¹ 18, Suppel. 1. – Ð. 5238 – 5242.


35. Hokeness K.L., Kuziel W.A., Biron C.A., Salazar-Mather T.P. Monocyte


chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced


inflammatory responses and antiviral defense in liver // J. Immunol. – 2005. – Vol. 174, ¹ 3. – Ð. 1549 – 1556.


36. Ip W.K., Lau Y.L. Role of mannose-binding lectin in the innate defense against


Candida albicans: enhancement of complement activation, but lack of opsonic function, in


phagocytosis by human dendritic cells // J. Infect. Dis. – 2004. – Vol. 190, ¹ 3. – Ð. 632 – 640.


37. Karrer S., Bosserhoff A.K., Weiderer P. et al. The -2518 promotor polymorphism in


the MCP-1 gene is associated with systemic sclerosis // J. Invest. Dermatol. – 2005. – Vol. 124,


¹ 1. – Ð. 92 – 98.


38. Kelly P., Jack D.L., Naeem A. et al. Mannose-binding lectin is a component of


innate mucosal defense against Cryptosporidium parvum in AIDS // Gastroenterology. – 2000. –


Vol. 119, ¹ 5. – Ð. 1236 – 1242.


39. Kinnman N., Andersson U., Hultcrantz R. In situ expression of transforming growth


factor-beta1-3, latent transforming growth factor-beta binding protein and tumor necrosis factoralpha


in liver tissue from patients with chronic hepatitis C // Scand. J. Gastroenterol. – 2000. –


Vol. 35, ¹ 12. – Ð. 1294 – 1300.


40. Kouki T., Gardine C.A., Yanagawa T., Degroot L.J. Relation of three


polymorphisms of the CTLA-4 gene in patients with Graves’disease // J. Endocrinol. Invest. –


2002. – Vol. 25, ¹ 3. – Ð. 208 – 213.


41. Koutsounaki E., Goulielmos G.N., Koulentaki M., et al. Mannose-binding lectin


MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients // J. Clin.


Immunol. – 2008. – Vol. 28, ¹ 5. – Ð. 495 – 500.


42. Larsen F., Madsen H.O., Sim R.B. et al. Disease-associated mutations in human


mannose-binding lectin compromise oligomerization and activity of the final protein // J. Biol.


Chem. – 2004. – Vol. 14, ¹ 20. – Ð. 21302 – 21311.


43. Le Roy F., Silhol M., Salehzada T., Bisbal C. Regulation of mitochondrial mRNA


stability by RNase L is translation-dependent and controls IFNalpha-induced apoptosis // Cell.


Death Differ. – 2007. – Vol. 14, ¹ 8. – Ð. 1406 – 1413.


44. Letendre S., Marquie-Beck J., Singh K.K. et al. The monocyte chemotactic


protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal


fluid // J. Neuroimmunol. – 2004. – Vol. 157, ¹ (1-2). – Ð. 193 – 196.


45. Ligers A., Teleshova N., Masterman T. et al. CTLA-4 gene expression is influenced


by promoter and exon 1 polymorphisms // Genes Immun. – 2001. – Vol. 2, ¹ 3. – Ð. 145 – 152.


46. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation // N.


Engl. J. Med. – 1998. – Vol. 338, ¹ 7. – Ð. 436 – 445.


47. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases


from behind the scenes into the spotlight // Am. J. Pathol. – 2007. – Vol. 171, ¹ 3. – Ð. 715 – 727.


48. Martin P., Lerner A., Johnson L. et al. Inherited mannose-binding lectin deficiency


as evidenced by genetic and immunologic analyses: association with severe recurrent


infections // Ann. Allergy Asthma Immunol. – 2003. – Vol. 91, ¹ 4. – Ð. 386 – 392.


49. Matsushita M., Hijikata M., Ohta Y. et al. Hepatitis C virus infection and mutations


of mannose-binding lectin gene MBL // Arch. Virol. – 1998. – Vol. 143, ¹ 4. – Ð. 645 – 651.


50. Matsushita M., Hijikata M., Matsushita M. et al. Association of mannose-binding


lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in


Japanese patients // J. Hepatol. – 1998. – Vol. 29, ¹ 5. – Ð. 695 – 700


51. Maurer M., Loserth S., Kolb-Maurer A. et al. A polymorphism in the human


cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation //


Immunogenetics. – 2002. – Vol. 54, ¹ 1. – Ð. 1 – 8


52. Muhlbauer M., Bosserhoff A.K., Hartmann A. et al. A novel MCP-1 gene


polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver


disease // Gastroenterology. – 2003. – Vol. 125, ¹4. – Ð. 1085 – 1093.


53. Nahon P, Sutton A., Rufat P., et al. Chemokine system polymorphisms, survival


and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis //


World J. Gastroenterol. – 2008. – Vol. 14, ¹ 5. – Ð. 713 – 719.


54. Najafian N., Sayegh M.H. CTLA4-Ig: a novel immunosuppressive agent // Expert.


Opin. Investig. Drugs. – 2000. – Vol. 9, ¹ 9. – Ð. 2147 – 2157.


55. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consensus


and State-of-the-Science Statements. – 2002, – Vol. 19, ¹3, – Ð.30.


56. Oaks M.K., Hallett K.M., Penwell R.T. et al. A native soluble form of CTLA-4 //


Cell Immunol. – 2000. – Vol. 201, ¹ 2. – Ð. 144 – 153.


57. Ostrov D.A., Shi W., Schwartz J.C. et al. Structure of murine CTLA-4 and its role


in modulating T cell responsiveness // Science. – 2000. – Vol. 290, ¹ 5492. – Ð. 816 – 819.


58. Pangburn M.K., Ferreira V.P., Cortes C. Discrimination between host and


pathogens by the complement system // Vaccine. – 2008. Vol. 26, Suppl 8. – P. 15 – 21.


59. Park Y.J., Chung H.K., Park D.J. et al. Polymorphism in the promoter and exon 1 of


thecytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans // Thyroid. – 2000. – Vol. 10, ¹ 6. – Ð. 453 – 459.


60. Patel K., Muir A.J., McHutchison J.G. Diagnosis and treatment of chronic hepatitis


C infection // BMJ. – 2006. – Vol. 332, ¹ 7548. – Ð. 1013 – 1017.


61. Peterslund N.A., Koch C., Jensenius J.C., Thiel S. Association between deficiency


of mannose-binding lectin and severe infections after chemotherapy // Lancet. – 2001. –


Vol. 358, ¹ 9282. – Ð. 637 – 638.


62. Petri B., Phillipson M., Kubes P. The physiology of leukocyte recruitment: an in


vivo perspective // J. Immunol. – 2008. – Vol. 180, ¹ 10. – Ð. 6439 – 6446.


63. Powell E.E., Edwards-Smith C.J., Hay J.L., Host genetic factors influence disease


progression in chronic hepatitis C // Hepatology. – 2000. – Vol. 31, ¹ 4. – Ð. 828 – 833


64. Poynard T., Ratziu V., Benmanov Y., Fibrosis in patients with chronic hepatitis C:


detection and significance // Semin. Liver Dis. – 2000. – Vol. 20, ¹ 1. – Ð. 47 – 55.


65. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between


induction, signalling, antiviral responses and virus countermeasures // J. Gen. Virol. – 2008. – Vol. 89, ¹ 1. – Ð. 1 – 47.


66. Ray S., Broor S.L., Vaishnav Y. et al. Transforming growth factor beta in hepatitis


C virus infection: in vivo and in vitro findings // J. Gastroenterol. Hepatol. – 2003. – Vol. 18, ¹ 4. – Ð. 393 – 403.


67. Rovin B.H., Lu L., Saxena R. A novel polymorphism in the MCP-1 gene regulatory


region that influences MCP-1 expression // Biochem. Bioph. Res. Com. – 1999. – Vol. 259. – Ð. 344 – 348.


68. Roy S., Knox K., Segal S. et al. MBL genotype and risk of invasive pneumococcal


disease: a case-control study // Lancet. – 2002. – Vol. 359, ¹ 9317. – Ð. 1569 – 1573.


69. Rudd C.E., Taylor A., Schneider H. CD28 and CTLA-4 coreceptor expression and


signal transduction // Immunol. Rev. – 2009. – Vol. 229, ¹ 1. – Ð. 12 – 26.


70. Sadler A.J., Williams B.R. Interferon-inducible antiviral effectors // Nat. Rev.


Immunol. – 2008. – Vol. 8, ¹ 7. – Ð. 559 – 568.


71. Sasaki K., Tsutsumi A., Wakamiya N. et al. Mannose-binding lectin


polymorphisms in patients with hepatitis C virus infection // Scand. J. Gastroenterol. – 2000. –


Vol. 35, ¹ 9. – Ð. 960 – 965.


72. Segat L., Silva Vasconcelos L.R., et al. Association of polymorphisms in the first


exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection // Clin. Immunol. – 2007. – Vol. 124, ¹ 1. – Ð. 13 – 17.


73. Seki E., de Minicis S., Inokuchi S., Taura K., Miyai K., van Rooijen N., Schwabe


R.F., Brenner D.A. CCR2 promotes hepatic fibrosis in mice // Hepatology. – 2009. – Vol. 50,


¹ 1. – Ð. 185 – 197.


74. Si Y., Tsou C.L., Croft K., Charo I.F. CCR2 mediates hematopoietic stem and


progenitor cell trafficking to sites of inflammation in mice // J. Clin. Invest. – 2010. – Vol. 120,


¹ 4. – Ð. 1192 – 1203.


75. Silverman R.H. A scientific journey through the 2-5A/RNase L system // Cytokine


Growth. Factor Rev. – 2007. – Vol. 18, ¹ 5-6. – Ð. 381 – 388.


76. Silverman R.H. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L


during the interferon antiviral response // J. Virol. – 2007. – Vol. 81, ¹ 23. – Ð. 12720 – 12729.


77. Soo H.M., Garzino-Demo A., Hong W. et al. Expression of a full-length hepatitis C


virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES // Virology. –


2002. – Vol. 303, ¹ 2. – Ð. 253 – 277.


78. Sumiya M., Super M., Tabona P. et al. Molecular basis of opsonic defect in


immunodeficient children // Lancet. – 1991. – Vol. 337, ¹ 8757. – Ð. 1569 – 1570.


79. Summerfield J.A., Ryder S., Sumiya M. et al. Mannose binding protein gene


mutations associated with unusual and severe infections in adults // Lancet. – 1995. – Vol. 345,


¹ 8954. – Ð. 886 – 889.


80. Summerfield J.A., Sumiya M., Levin M., Turner M.W. Association of mutations in


mannose binding protein gene with childhood infection in consecutive hospital series // BMJ. –


1997. – Vol. 314, ¹ 7089. – Ð. 1229 – 1232.


81. Tag C.G., Mengsteab S., Hellerbrand C. et al. Analysis of the transforming growth


factor-beta1 (TGF-beta1) codon 25 gene polymorphism by LightCycler-analysis in patients with


chronic hepatitis C infection // Cytokine. – 2003. – Vol. 24, ¹ 5. – Ð. 173 – 181.


82. Taylor A.W. Review of the activation of TGF-beta in immunity // J. Leukoc. Biol. –


2009. – Vol. 85, ¹ 1. – Ð. 29 – 33.


83. Terai I., Kobayashi K., Matsushita M. et al. Relationship between gene


polymorphisms of mannose-binding lectin (MBL) and two molecular forms of MBL // Eur. J.


Immunol. – 2003. – Vol. 33, ¹ 10. – Ð. 2755 – 2763.


84. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune


attenuator // Immunity. – 1997. – Vol. 7, ¹ 4. – Ð. 445 – 450.


85. Vaidya B., Oakes E.J., Imrie H. et al. CTLA4 gene and Graves' disease: association


of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the


promoter polymorphism // Clin. Endocrinol. – 2003. – Vol. 58, ¹ 6. – Ð. 732 – 735.


86. Valdimarsson H., Stefansson M., Vikingsdottir T. et al. Reconstitution of


opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans //


Scand. J. Immunol. – 1998. – Vol. 48, ¹ 2. – Ð. 116 – 123.


87. Valdimarsson H., Vikingsdottir T., Bang P. et al. Human plasma-derived mannosebinding


lectin: a phase I safety and pharmacokinetic study // Scand. J. Immunol. – 2004. –


Vol. 59, ¹ 1. – Ð. 97 – 102.


88. Valdimarsson H. Infusion of plasma-derived mannan-binding lectin (MBL) into


MBL-deficient humans // Biochem. Soc. Trans. – 2003. – Vol. 31, ¹ 4. – Ð. 768 – 769.


89. van de Wetering J.K., van Golde L.M., Batenburg J.J. Collectins: players of the


innate immune system // Eur. J. Biochem. – 2004. – Vol. 271, ¹ 7. – Ð. 1229 – 1249.


90. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system:


turning lymphocytes off // Science. – 1998. – Vol. 280, ¹ 5361. – Ð. 243 – 248.


91. Verrecchia F., Mauviel A. Transforming growth factor-beta and fibrosis // World J.


Gastroenterol. – 2007. – Vol. 13, ¹ 22. – Ð. 3056 – 3062.


92. Vidigal P.G., Germer J.J., Zein N.N. Polymorphisms in the interleukin-10, tumor


necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients


treated with interferon and ribavirin // J. Hepatol. – 2002. – Vol. 36, ¹ 2. – Ð. 271 – 277.


93. Wang H., Mengsteab S., Tag C.G. et al. Transforming growth factor-beta1 gene


polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic


hepatitis C infection // World J G.astroenterol. – 2005. – Vol. 11, ¹ 13. – Ð. 1929 – 1936.


94. Wang S., Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family //


Cell. Mol. Immunol. – 2004. – Vol. 1, ¹ 1. – Ð. 37 – 42.


95. Washenberger C.L., Han J.Q., Kechris K.J., Jha B.K., Silverman R.H., Barton D.J.


Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L // Virus Res. – 2007. – Vol. 130, ¹ 1–2. – Ð. 85 – 95.


96. Wynn T.A. Cellular and molecular mechanisms of fibrosis // J. Pathol. – 2008.


– Vol. 214, ¹ 2. – Ð. 199 – 210.


97. Xiang Y., Wang Z., Murakami J. et al. Effects of RNase L mutations associated


with prostate cancer on apoptosis induced by 2',5'-oligoadenylates // Cancer Res. – 2003. – Vol. 63, ¹ 20. – Ð. 6795 – 67801.


98. Yee L.J., Perez K.A., Tang J. et al. Association of CTLA4 polymorphisms with


sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection // J.


Infect. Dis. – 2003. – Vol. 187, ¹ 8. – Ð. 1264 – 1271.


99. Yokota M., Ichihara S., Lin T.L. et al. Association of a T29-->C polymorphism of


the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in


Japanese // Circulation. – 2000. – Vol. 101, ¹ 24. – Ð. 2783 – 2787